Pfizer (PFE.US), BioNTech (BNTX.US) shares rose 3% and 11% respectively after FDA granted full U.S. approval of their Covid-19 vaccine for use in people aged 16 and older. FDA had been under rising pressure from the scientists and advocacy groups to fully approve Pfizer and BioNTech’s vaccine ever since both companies submitted their application to the agency in early May. Now FDA officials hope that today's approval will convince more unvaccinated Americans that Pfizer's shot is safe and effective. "While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated," said Janet Woodcock, the FDA's acting commissioner. Additionally, the U.K. has signed a deal for an additional 35 million vaccines from the two companies. Meanwhile Moderna (MRNA.US) is also in the process of applying for full FDA approval of its Covid-19 vaccine and its shares jumped over 6%.
BioNTech (BNTX.US) stock launched today's session with a bullish price gap and is currently approaching the major resistance zone around $400.00 which coincides with 23.6% Fibonacci retracement of the last upward wave and upper limit of the 1:1 structure. Should break higher occur, then upward move may accelerate towards all-time high at $463.80. On the other hand, the key support zone lies between $330.00 and $362.00 levels. Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThe content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
